TITLE

The Microbiological Eradication Rate of First-Line Antibiotic Treatment is a Key Cost Driver in the Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis

AUTHOR(S)
Lacey, L.F.; Volmer, T.; Harris, A.M.
PUB. DATE
December 1999
SOURCE
Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p276
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Investigates the relationship between microbiological efficacy and clinical efficacy of first-line treatment in acute bacterial exacerbations of chronic bronchitis. Materials and methods; Results; Discussion.
ACCESSION #
9593500

 

Related Articles

  • Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial. Chatterjee, S.; Biswas, T.; Dutta, A.; Sengupta, G.; Mitra, A.; Kundu, S. // Indian Journal of Pharmacology;Feb2011, Vol. 43 Issue 1, p40 

    Objective: Acute exacerbation of chronic bronchitis (AECB) is a commonly encountered problem and those suspected to be due to bacterial infections require antibiotic therapy. This randomized, controlled trial was designed to evaluate the effectiveness and safety of gemifloxacin, a new...

  • Cefprozil.  // AHFS Consumer Medication Information;Aug2019, p1 

    Cefprozil is used to treat certain infections caused by bacteria, such as bronchitis and infections of the ears, throat, sinuses, and skin. Cefprozil is in a class of medications called cephalosporin antibiotics. It works by stopping the growth of bacteria. Antibiotics will not work for colds,...

  • Ceftibuten.  // AHFS Consumer Medication Information;Aug2019, p1 

    Ceftibuten is a cephalosporin antibiotic used to treat certain infections caused by bacteria such as bronchitis and ear and throat infections. Antibiotics will not work for colds, flu, or other viral infections. This medication is sometimes prescribed for other uses; ask your doctor or...

  • Cefpodoxime.  // AHFS Consumer Medication Information;Aug2019, p1 

    Cefpodoxime is a cephalosporin antibiotic used to treat certain infections caused by bacteria such as pneumonia; bronchitis; gonorrhea; and ear, skin, throat, and urinary tract infections. Antibiotics will not work for colds, flu, or other viral infections. This medication is sometimes...

  • Amoxicillin.  // AHFS Consumer Medication Information;Aug2019, p1 

    Amoxicillin is used to treat certain infections caused by bacteria, such as pneumonia; bronchitis; gonorrhea; and infections of the ears, nose, throat, urinary tract, and skin. It is also used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers....

  • Clarithromycin.  // AHFS Consumer Medication Information;Aug2019, p1 

    Clarithromycin is used to treat certain infections caused by bacteria, such as pneumonia (a lung infection), bronchitis (infection of the tubes leading to the lungs), and infections of the ears, sinuses, skin, and throat. It also is used to treat and prevent disseminated Mycobacterium avium...

  • INFECTIONS & INFESTATIONS.  // MPR - Pediatricians' Edition;Fall2009/Winter2010, Vol. 20 Issue 2, p168 

    The article presents medications for the treatment of bacterial infections in the U.S. GlaxoSmithKline's Amoxil Amoxicillin capsule is for ear, nose, throat (ENT), and lower respiratory tract infection. Ortho-McNiel Pharmaceutical Inc.'s Ofloxacin tablet is for acute bacterial exacerbation of...

  • Cefdinir.  // AHFS Consumer Medication Information;Aug2019, p1 

    Cefdinir is an antibiotic used to treat certain infections caused by bacteria, such as pneumonia, bronchitis, ear infections, sinusitis, pharyngitis, tonsillitis, and skin infections. Antibiotics will not work for colds, flu, or other viral infections. This medication is sometimes prescribed for...

  • Bronchiolitis. Isaacs, David // BMJ: British Medical Journal (International Edition);1/7/95, Vol. 310 Issue 6971, p4 

    Editorials. Discusses the treatment of bronchiolitis. Cause in 70 percent of the cases; Distinction from infantile asthma; Partial immunity conferred by transplacental maternal antibody; Risk of the lower respiratory tract being affected in respiratory syncytial viral infection.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics